ClinicalTrials.gg
RecruitingNCT04318899Updated Oct 16, 2026

Predictors of Clinical Course and Treatment Response in DBT Programmes

An interventional study of Dialectical Behaviour Therapy adapted for adolescents (DBT-A) and Dialectical Behaviour Therapy - Standard version (DBT) in Self Harm and Borderline Personality Disorder, sponsored by Oslo University Hospital. Recruiting at 5 sites in Norway. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Jan 2018, registered Mar 2020).
  • Started Jan 2018; still recruiting 8 years 10 months later.
Updated Oct 16, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
12 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Self-Injurious Behavior with a site in Norway — 5 open to participants now, 5 under way, none of them phase 3. Self-Injurious Behavior · Norway.

Started
2018
the only one that year
No phase
8 of 11
5 open now
Registered
7th of 11
by date
Lead sponsor
6 of 11
Oslo University Hospital

Among the 11 studies in Self-Injurious Behavior with a site in Norway, this one is the only one that started in 2018, is one of 8 with no phase, and was the 7th registered.

Self-Injurious Behavior

303 studies on the registry are indexed under Self-Injurious Behavior; 105 are open to participants now.

Browse Self-Injurious Behavior studies →

Open to participants now

5 of the 11 studies in Self-Injurious Behavior with a site in Norway are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 69 Self-Injurious Behavior studies recruiting now, 16 (23%) set no upper age limit and 51 (74%) stop at 75 or younger; 46 take children under 18; 12 take healthy volunteers.

This study: 12 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Self-Injurious Behavior with a site in Norway, or all of them as a file.
02

Study summary

The project is a collaboration between The National Centre for Suicide Research and Prevention (NSSF) and clinical units with Dialectical Behaviour Therapy (DBT) programmes. A methodological and technological platform has been established that enables clinicians to deliver high quality treatments over extended periods of time, to evaluate their own performance and productivity and to report it in a uniform and systematic way that will enable comparison across clinical settings and programmes. The collected data constitute the basis for conducting the clinical study with the overall aim to study predictors of the clinical course and treatment response in patients admitted to DBT programmes in Norway.

Read the detailed description

The aim of the project is to collect data from systematic and uniform clinical assessments to study predictors of the clinical course and treatment response in patients admitted to and treated in clinical units delivering Dialectical Behaviour Therapy in Norway.

Aims and research questions:

The study will address the following main research questions:

  1. Which patient characteristics (sociodemographic variables, psychiatric diagnoses/comorbidities, previous suicidal and self-harming behaviour, previous treatment history), predict a favourable clinical course and treatment response?
  2. Which factors mediate the clinical change in key outcomes such as a) target symptom levels (depression, hopelessness, suicidal ideation, borderline symptoms etc.), b) function levels (emotion regulation capacity, use of coping skills, social functioning, occupational / academic performance level etc.), c) problem behaviours (suicide attempts, non-suicidal self-harm, substance abuse, eating disorder symptoms etc.), d) global functioning and e) the use of emergency treatment services.
  3. What are significant moderators of treatment response with respect to key clinical outcomes (mentioned above)?
  4. Which of the treatment modalities are evaluated as the most salient and helpful by patients who receive the treatment according to their age, gender, psychiatric diagnoses and previous treatment history?

Methods:

A uniform protocol for psychiatric diagnostics and clinical assessment of patients who receive treatment at the participating clinical units will be used. Since some participating clinical units will treat adult patients and some will treat children and adolescents, the protocol will offer assessment instrument suitable for the specific age group whenever this is relevant. The evaluation system includes assessments at baseline before treatment starts, evaluation at several time points during the treatment period, at termination of treatment and at follow-up. Assessments will be made both through interviews and ratings made by therapists and through self-report from patients.

Self-reports will be filled out electronically by patients, on tablets stationed at each participating clinical unit. At intervals patients will also provide self-rated information on dimensions such as emotions, cognitions and impulsive behaviour several times per day through a mobile app developed specifically for the purpose, so-called Ecological Momentary Assessment (EMA). Interview data and ratings will be entered into the database by each clinician to tablets in a similar fashion as self-report data from patients.

03

Conditions studied

  • Self Harm
  • Borderline Personality Disorder

Keywords

  • self harm
  • dialectical behaviour therapy
  • borderline personality disorder
  • emotional dysregulation
04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of repeated deliberate self harm
  • Satisfies criteria of Diagnostic and Statistical Manual () Borderline Personality Disorder as measured by Structured Clinical Interview for the DSM (SCID-II) in addition to the self-destructive criterion.

Exclusion criteria

Exclusion Criteria:

  • Psychotic disorders
  • Anorexia Nervosa
  • Substance dependence disorder
  • Mental retardation (IQ less than 70)
  • Asperger syndrome/autism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Dialectical Behaviour Therapy

    Dialectical Behavior Therapy, delivered for 20 weeks for adolescents (DBT-A) or 52 weeks for adults (standard DBT.

    Behavioral: Dialectical Behaviour Therapy adapted for adolescents (DBT-A) · Behavioral: Dialectical Behaviour Therapy - Standard version (DBT)

Interventions

  • BehavioralDialectical Behaviour Therapy adapted for adolescents (DBT-A)

    DBT developed by Marsha Linehan (Linehan 1993a; 1993b) and adapted for adolescents (DBT-A) by Miller, Rathus \& Linehan, 2007 consisting of 20 weeks of weekly individual therapy (60 minutes), multifamily skills training (120 minutes), family therapy sessions as needed and telephone coaching outside therapy sessions.

  • BehavioralDialectical Behaviour Therapy - Standard version (DBT)

    DBT developed by Marsha Linehan (Linehan 1993a, 1993 b) consisting of 1 weekly session of individual therapy (60 minutes), 1 weekly session of skills training (120 minutes), and telephone coaching with individual therapists outside therapy sessions as needed.

06

What researchers measure

Primary outcomes

  1. Self-harm behaviour

    Number of self-harm episodes (split on suicide attempts and non-suicidal self-harm)

    Time frame: 4 weeks

  2. Suicidal Ideation (adolescents)

    Suicidal Ideation Questionnaire (SIQ-Jr). Min=0, Max=90. Higher scores indicate worse outcome

    Time frame: 2 weeks

  3. Depressive symptoms

    MADRS (Montgomery Asberg Depression Rating Scale).Min=0, Max=60. Higher scores indicate worse outcome

    Time frame: 1 week

  4. Suicidal Ideation (adults)

    Beck Scale for Suicidal Ideation (BSS). MIn=0, Max=38. Higher scores indicate worse outcome

    Time frame: 4 weeks

  5. Depressive symptoms (adolescents)

    Moods and Feelings Questionnaire (MFQ). Min=0, Max=26. Higher scores indicate worse outcome

    Time frame: 1 week

  6. Depressive symptoms (adults)

    Beck Depression Inventory (BDI). Min=0, Max=63. Higher scores indicate worse outcome

    Time frame: 1 week

Secondary outcomes

  1. Borderline Symptoms

    Borderline Symptom List (BSL-23). Min=0, Max=92. Higher scores indicate more symptoms.

    Time frame: 1 week

  2. Hopelessness

    Beck Hopelessness Scale (BHS). Min=0, Max=20. Higher scores indicate more hopelessness.

    Time frame: 1 week

07

Study locations

5 of 5 sites recruiting
  • Søndre Oslo DPS/Oslo Universitetssykehus HF
    Oslo, Oslo 1281, Norway
    Recruiting
  • Moss DPS/Østfold sykehus HF
    Moss, 1535, Norway
    Recruiting
  • Psykiatrisk senter ytre Helgeland/Helgelandssykehuset HF
    Sandnessjøen, 8800, Norway
    Recruiting
  • Bjerketun behandlingshjem/Vestreviken HF
    Sandvika, 1341, Norway
    Recruiting
  • BUP Lian/St Olavs Hospital HF
    Trondheim, 7024, Norway
    Recruiting
08

References and documents

Publications

  • Linehan, M.M. (1993a). Cognitive-behavioral treatment of borderline personality disorder. New York: Guilford Press
  • Linehan, M.M. (1993b). Skills training manual for treating borderline personality disorder. New York: Guilford Press
  • Miller, A.L., Rathus J.H., Linehan, M.M. (2007). Dialectical behavioral therapy with suicidal adolescents. New York: Guilford Press

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2018 (actual). Primary completion is estimated for Dec 2029, 143 months after the start.

Of 162 non-industry interventional studies with no phase under Self-Injurious Behavior, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 53. This study's planned 143 months is above that.

Counting every sponsor, half of 164 studies reached it within 28 months; a quarter within 15 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Dec 2025 → Dec 2029 and completion Dec 2025 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2020
First posted
Mar 24, 2020
StartActual
Jan 1, 2018
Primary completionEst.
Dec 31, 2029was Dec 2025
CompletionEst.
Dec 31, 2029was Dec 2025
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Søndre Oslo DPS/Oslo Universitetssykehus HF · Oslo, Norway
Show 1 removed
  • Søndre Oslo DPS/Oslo Universitetssykehus HF · Oslo, Norway
Oct 16, 2026
Primary completion
Dec 31, 2025→Dec 31, 2029
Oct 16, 2026
Study completion
Dec 31, 2025→Dec 31, 2029
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    1 site added, 1 site removed
    Show site
    • Søndre Oslo DPS/Oslo Universitetssykehus HF · Oslo, Norway
    Show 1 removed
    • Søndre Oslo DPS/Oslo Universitetssykehus HF · Oslo, Norway
    Primary completion Dec 31, 2025→Dec 31, 2029
    Study completion Dec 31, 2025→Dec 31, 2029
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04318899
Collaborators
Vestre Viken Hospital Trust, St. Olavs Hospital, Sykehuset Ostfold, University of Oslo, Nordlandssykehuset HF
Responsible party
Lars Mehlum (Professor dr med, Oslo University Hospital) — Principal investigator
First posted
Mar 24, 2020
Start date
Jan 1, 2018
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 16, 2026

Study contacts

Egil Haga, PhD
Contact
egil.haga@medisin.uio.no
+4722923442
Lars Mehlum, MD PhD
Contact
lars.mehlum@medisin.uio.no
+4722923442
Lars Mehlum, MD PhD
principal investigator · University of Oslo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion